PEG-MGF

Read 1. One verified 56-year-old male reported a four-week PEG-MGF cycle, but it was combined with IGF-1 LR3 and testosterone therapy, leaving the PEG-MGF-specific outcome unclear. Among seven coded users overall, isolated claims included improved tendon recovery or muscle growth, alongside reports of no noticeable benefit or short-lived training effects. Some people described discomfort associated with intramuscular administration, and one described a rebound in training performance afterward. Reports often blur PEG-MGF with unmodified MGF or combine it with other growth-related compounds. The evidence is particularly unreliable because the number of usable accounts is very small and compound identity or purity was not independently verified.

Read 2. No man aged 45–60 and no stated man; one self-reporter in total, who takes it 30 minutes post-workout and asked about meal timing without reporting any outcome. Three of four threads were prospective dosing questions. No conclusions possible.

Note 1. The 56M user's outcome was unclear, not a confirmed no-effect result; the quote stance denotes absence of demonstrated efficacy rather than his stated verdict. Plain-MGF-only discussion was excluded. Some accounts mention both PEG-MGF and other growth factors without separately measuring outcomes. No evidence of an independently confirmed product identity or standardized exposure was found. Counts represent a selected set of verifiable reports.

Note 2. Extremely sparse: 3 of 4 threads were questions, and three r/steroids seed threads were not retrievable.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.